{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T23:06:47Z","timestamp":1779577607439,"version":"3.53.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,20]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Sintilimab, an immune checkpoint inhibitor, enhances T-cell responses, leading to robust antitumor activity, and is approved for the treatment of lung cancer. While immune checkpoint inhibitors offer substantial clinical benefits, they are often associated with immune-related adverse events, particularly cutaneous toxicities. These skin reactions typically manifest as mild maculopapular rashes; however, more severe manifestations, such as Stevens\u2013Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), can occur. Both SJS and TEN are life-threatening conditions with high mortality rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>\n                      The patient in this case is a 68-year-old male diagnosed with stage IVA non-small cell lung cancer, who has no detectable oncogenic mutations. He was treated with sintilimab (200\u2009mg), pemetrexed disodium (500\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), and cisplatin (75\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). Following the third cycle of therapy, he developed widespread skin blisters, localized necrosis, and severe pain on the second day.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient\u2019s symptoms \u2013 widespread skin blisters, localized necrosis, and severe pain \u2013 were indicative of SJS and TEN, which are immune-related cutaneous toxicities triggered by immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Immediate interventions were initiated, which included systemic corticosteroids, anti-inflammatory treatments, fluid replacement, and appropriate skin care measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>These interventions led to significant improvement in the immunotherapy-related dermatologic toxicity experienced by the patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case underscores the importance for clinicians to remain vigilant regarding severe cutaneous toxicities such as SJS and TEN in patients undergoing sintilimab-based therapy. Prompt recognition and intervention are essential to mitigate the risks associated with these potentially life-threatening conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047805","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:01:02Z","timestamp":1771628462000},"page":"e47805","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Stevens-Johnson syndrome\/toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer: A case report"],"prefix":"10.1097","volume":"105","author":[{"given":"Yanli","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Shanxi Cancer Hospital, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shanxi Cancer Hospital, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shanxi Cancer Hospital, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhong","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shanxi Cancer Hospital, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shanxi Cancer Hospital, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shanxi Cancer Hospital, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liang","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Zhao","sequence":"additional","affiliation":[{"name":"Kindstar Global Precision Medicine Institute, Wuhan, China"},{"name":"Wuhan Kindstar Zhenyuan Medical Laboratory Co. Ltd, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Kindstar Global Precision Medicine Institute, Wuhan, China"},{"name":"Wuhan Kindstar Zhenyuan Medical Laboratory Co. Ltd, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7772-3686","authenticated-orcid":false,"given":"Jinfang","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shanxi Cancer Hospital, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260523","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R2-20260523","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.jaad.2017.08.028","article-title":"Vitiligo-like lesions in patients receiving anti-programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo.","volume":"78","author":"Boniface","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R3-20260523","doi-asserted-by":"crossref","first-page":"1164692","DOI":"10.3389\/fendo.2023.1164692","article-title":"A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011-2021.","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R4-20260523","article-title":"Bibliometric analysis of immune-related acute kidney injury induced by cancer immunotherapy (2000-2025).","author":"Zhang","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R5-20260523","doi-asserted-by":"crossref","first-page":"e71317","DOI":"10.1002\/cam4.71317","article-title":"Metabolic reprogramming in lung cancer: hallmarks, mechanisms, and targeted strategies to overcome immune resistance.","volume":"14","author":"Chen","year":"2025","journal-title":"Cancer Med"},{"key":"R6-20260523","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1081-1206(10)60078-6","article-title":"Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.","volume":"102","author":"Lee","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R7-20260523","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jamaoncol.2025.4349","article-title":"Immune checkpoint inhibitors as independent and synergistic drivers of SJS\/TEN.","volume":"11","author":"Milan Mukherjee","year":"2025","journal-title":"JAMA Oncol"},{"key":"R8-20260523","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2500\/108854192778878926","article-title":"Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS.","volume":"13","author":"Patterson","year":"1992","journal-title":"Allergy Proc"},{"key":"R9-20260523","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ijd.13379","article-title":"A retrospective analysis of Stevens-Johnson syndrome\/toxic epidermal necrolysis treated with corticosteroids.","volume":"55","author":"Liu","year":"2016","journal-title":"Int J Dermatol"},{"key":"R10-20260523","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1001\/jamadermatol.2022.4543","article-title":"Systemic interventions for treatment of stevens-johnson syndrome\/toxic epidermal necrolysis: summary of a cochrane review.","volume":"158","author":"Noe","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R11-20260523","doi-asserted-by":"crossref","first-page":"594558","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: a promising anti-tumor PD-1 antibody.","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"R12-20260523","doi-asserted-by":"crossref","first-page":"100951","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database.","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R13-20260523","doi-asserted-by":"crossref","first-page":"47","DOI":"10.55940\/medphar202567","article-title":"MDM2 antagonists and p53-targeting therapies in cancer: clinical applications, adverse effects, and resistance mechanisms.","volume":"4","author":"Almukram","year":"2025","journal-title":"Med Pharm J"},{"key":"R14-20260523","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020.","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R15-20260523","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events.","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R16-20260523","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","article-title":"Cyclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174 patients-exposed\/unexposed and propensity score-matched analyses.","volume":"138","author":"Poizeau","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R17-20260523","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated stevens-johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T23:00:49Z","timestamp":1779577249000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047805","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"2025-08-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}